Program Overview

This live virtual mini-symposium brings together leading voices in pancreatic oncology to translate the first-ever U.S. consensus statements on exocrine pancreatic insufficiency (EPI) into practical, everyday clinical care. Despite affecting an estimated 70% of patients with pancreatic cancer, EPI remains widely under-recognized and under-treated, leaving many patients to suffer preventable symptoms, malnutrition, and reduced treatment tolerance. Featured speakers will unpack the new consensus screening and treatment framework in a moderated Q&A format, offering attendees actionable strategies to identify EPI earlier and manage it more effectively across the care continuum.

Learning Objectives

By the end of this webinar, participants will be able to:

1. Describe the prevalence and clinical impact of EPI across the pancreatic cancer care continuum.

2. Apply consensus-based screening criteria to identify patients who may benefit from pancreatic enzyme replacement therapy (PERT), without reliance on pancreatic function testing.

3. Implement evidence-informed PERT dosing, titration, and monitoring practices, including strategies to address common barriers to adherence.

4. Identify opportunities to integrate multidisciplinary collaboration and EPI screening into existing oncology workflows.